These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24550402)

  • 41. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
    Legrand N; Huntington ND; Nagasawa M; Bakker AQ; Schotte R; Strick-Marchand H; de Geus SJ; Pouw SM; Böhne M; Voordouw A; Weijer K; Di Santo JP; Spits H
    Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13224-9. PubMed ID: 21788504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A).
    Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080360
    [No Abstract]   [Full Text] [Related]  

  • 45. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
    Wu F; Qiu Y; Xu Y
    Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.
    Seiffert M; Brossart P; Cant C; Cella M; Colonna M; Brugger W; Kanz L; Ullrich A; Bühring HJ
    Blood; 2001 May; 97(9):2741-9. PubMed ID: 11313266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 'Clustering' SIRPα into the plasma membrane lipid microdomains is required for activated monocytes and macrophages to mediate effective cell surface interactions with CD47.
    Ha B; Lv Z; Bian Z; Zhang X; Mishra A; Liu Y
    PLoS One; 2013; 8(10):e77615. PubMed ID: 24143245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling.
    Koskinen C; Persson E; Baldock P; Stenberg Å; Boström I; Matozaki T; Oldenborg PA; Lundberg P
    J Biol Chem; 2013 Oct; 288(41):29333-44. PubMed ID: 23990469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
    Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
    Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crystal structure of signal regulatory protein gamma (SIRPγ) in complex with an antibody Fab fragment.
    Nettleship JE; Ren J; Scott DJ; Rahman N; Hatherley D; Zhao Y; Stuart DI; Barclay AN; Owens RJ
    BMC Struct Biol; 2013 Jul; 13():13. PubMed ID: 23826770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure of the human marker of self 5-transmembrane receptor CD47.
    Fenalti G; Villanueva N; Griffith M; Pagarigan B; Lakkaraju SK; Huang RY; Ladygina N; Sharma A; Mikolon D; Abbasian M; Johnson J; Hadjivassiliou H; Zhu D; Chamberlain PP; Cho H; Hariharan K
    Nat Commun; 2021 Sep; 12(1):5218. PubMed ID: 34471125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design single-stranded DNA aptamer of cluster of differentiation 47 protein by stochastic tunnelling-basin hopping-discrete molecular dynamics method.
    Yang HW; Ju SP; Hsieh YT; Yang YC
    J Biomol Struct Dyn; 2024 May; 42(8):3969-3982. PubMed ID: 37261868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
    Bouwstra R; van Meerten T; Bremer E
    Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
    Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor.
    Tanaka K; Miyoshi H; Kawamoto K; Shimasaki Y; Nakashima K; Imamoto T; Yamada K; Takeuchi M; Moritsubo M; Furuta T; Kohno K; Tamura S; Sonoki T; Ohshima K
    Pathology; 2024 Feb; 56(1):81-91. PubMed ID: 38110323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.
    De Vlaminck K; Romão E; Puttemans J; Pombo Antunes AR; Kancheva D; Scheyltjens I; Van Ginderachter JA; Muyldermans S; Devoogdt N; Movahedi K; Raes G
    Front Immunol; 2021; 12():777524. PubMed ID: 34917090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.